HomeAI · summaries
Storia in 4 fonti
Topline data: Zasocitinib outperforms deucravacitinib for plaque psoriasis
Zasocitinib outperformed deucravacitinib for the treatment of patients with moderate to severe plaque psoriasis, according to topline data. As Healio previously reported, zasocitinib (Takeda) is an investigational, highly selective oral tyrosine kinase 2 (TYK2) inhibitor that blocks interleukin-23 and other pathways driving psoriasis. In the phase 3, head-to-head trial, researchers found that
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
- ·
fiercebiotech.com
Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown
Takeda has won the battle of the TYK2 inhibitors, toppling Bristol Myers Squibb’s Sotyktu to strengthen its hand ahead of an anticipated plaque psoriasis launch next year. |…
